SCSC screens as a value-led small-cap compounder after a clean Q4 FY26 beat, strong free-cash-flow conversion and a nearly ungeared balance sheet. The fair value is only moderately above the last close, so the thesis depends on FY27 guidance delivery and disciplined MicroAge integration rather than multiple expansion alone.
The implied base-case multiple is roughly 8.0x blended FY27E EBITDA, below the peer median near 10.9x and within the observable distributor peer range. Cross-check by forward EPS: $64.50 / FY26 non-GAAP EPS $4.24 = 15.2x, reasonable versus a forward P/E near 11.8x before guidance rerating but above the most conservative analyst target. Sensitivity: +/-1.0x EBITDA multiple moves fair value by about +/-$8 per share, so the valuation is moderately multiple-sensitive. Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| Specialty Technology Solutions EV | ~$129M FY27E EBITDA allocation x 7.5x risk-adjusted distributor multiple / 20.14M shares | +48.00 |
| Intelisys & Advisory EV | ~$32.5M FY27E EBITDA allocation x 11.0x higher-margin recurring/channel multiple / 20.14M shares | +17.80 |
| Net debt bridge | ($88.4M cash - $110.9M debt) / 20.14M shares before MicroAge closing | -1.12 |
| MicroAge option value | 25% probability x $80M integration value from cloud/cyber/MSP cross-sell / 20.14M shares | +0.99 |
| Working-capital and deal reserve | -$25M reserve for Q4 FCF volatility and $220.5M cash acquisition execution risk / 20.14M shares | -1.24 |
| FV base case | Explicit sum: 48.00 + 17.80 - 1.12 + 0.99 - 1.24 | 64.43 |
Insider flow is the main capital-structure caution: recent Form 4 datasets show meaningful net insider selling through early September 2026, including an SVP sale around $304K. It is not thesis-breaking, but it reduces the management score until buying or retention offsets the sales.
| Item | FY2024 | FY2025 | FY2026 | FY2027E | Guidance 2027 |
|---|---|---|---|---|---|
| Net sales | N/D | $3.04B | $3.23B | $3.42B-$3.55B | +6% to +10% |
| Gross profit | N/D | $408.6M | $437.4M | N/D | Mix benefit expected from MicroAge after close |
| Adjusted EBITDA | N/D | $144.7M | $151.5M | $158M-$165M | 4.6%-4.65% margin |
| Non-GAAP EPS | N/D | $3.57 | $4.24 | N/D | Acquisition expected accretive in first year |
| Free cash flow | N/D | N/D | $113.8M | At least $85M | Excludes MicroAge impact |
| Metric | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|
| Revenue ($M) | 812.9 | 739.7 | 760.1 | 766.8 | 953.1 |
| Gross margin % | 12.9% | N/D | N/D | N/D | 12.6% |
| Net income ($M) | 20.1 | N/D | N/D | N/D | 25.6 |
| End-of-period cash ($M) | N/D | N/D | N/D | N/D | 88.4 |
Business model - specialty technology distribution
Specialty Technology Solutions ~$927M Q4 FY26 segment revenue ramping Hardware-led distribution across barcode, POS, networking, communications and security. Scale drives operating leverage, but working capital swings with demand. Intelisys & Advisory ~$26M Q4 FY26 revenue, high EBITDA margin ramping Connectivity, cloud, CX, data center and advisory model. Smaller revenue base but structurally higher margins and better recurring visibility. MicroAge pending $220.5M cash acquisition to prove Adds MSP, cybersecurity, data center and AI services. It should be accretive, but debt-funded M&A raises integration and capital allocation risk.
Legal, regulatory and risk analysis
SWOT analysis
- +Low leverage and strong FY26 FCF conversion.
- +Q4 FY26 revenue and EPS beat with 17.3% quarterly sales growth.
- +Buybacks are material relative to market cap.
- −Core distribution margins remain thin.
- −Return on equity is not exceptional despite good adjusted ROIC.
- −Analyst targets are mixed after the share price rally.
- →MicroAge can lift gross margin mix and expand managed-services reach.
- →FY27 organic revenue guide leaves room for earnings revisions.
- →Peer multiple gap can close if FCF remains clean.
- !Acquisition debt may crowd out buybacks.
- !Hardware demand can normalize after a strong Q4.
- !Working-capital builds can obscure earnings quality.
Summary by assessment area
- Net leverage is near zero before the deal.
- FY26 free cash flow conversion was strong.
- MicroAge is the main strategic catalyst and risk.
- Brazil and working capital need monitoring.
- Base FV is $64.50, about +13% versus last close.
- The upside is real but not wide enough to ignore execution.
Sources: Yahoo Finance and YCharts/MarketBeat price data; ScanSource FY26 press release and FY27 outlook; SEC 10-K and 8-K filings; MarketBeat/FINRA short-interest data; StockAnalysis/Yahoo/Quanteia peer valuation data for SNX, ARW and AVT. MARKET_DATA_AS_OF_DATE: SCSC ~$56.88 close on Sep 18, 2026; market cap ~$1.15B; 52W range ~$33.76-$66.78; shares outstanding ~20.14M; short interest 4.61% of float. This document is for informational purposes only and does not constitute financial or investment advice.